Ultrasound-Driven Coassembly of Anticancer Drugs into Carrier-Free Particles

Abstract

The evolution of drug resistance in tumor malignancies has necessitated advancements in anticancer drug therapy. Drug combination therapy, which can burden cancer progression at multiple target sites, has been used to address drug resistance and includes the coencapsulation of synergistic drugs within nanoparticle carriers. However, the use of organic and inorganic carriers can lead to additional material-induced safety concerns, including inflammation and antibody formation. Herein, we report an ultrasound-driven approach to combine synergistic anticancer drugs into carrier-free particles. Venetoclax (Vtx) (as a model anticancer drug) is combined with an anticancer anthracycline drug, doxor..